Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Do ...

Beam Therapeutics (BEAM) reported a loss of $1.09 per share for the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The company had recorded earnings of $1.73 per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues, comprising license and collaboration revenues, came in at $30.1 million in the fourth quarter compared with $316.2 million reported in the year-ago period. The top line beat the Zacks Co ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.91%. A quarter ago, it was expected that this company would post a loss of $1.13 per share when it actually produced a loss of $1.17, delivering a surprise of -3.54%.Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39208 Beam Therapeutics Inc. (Mark One) FORM 10-K OR Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO For the fiscal year ended December 31, 2024 238 Main Street (Address of principal executive of ices) (Zip Code) Common Stock, par value $0.01 per sh ...

Financial Position - As of December 31, 2024, Beam Therapeutics Inc. estimates cash, cash equivalents, and marketable securities of approximately $850.7 million[6] - The estimated cash balance is preliminary and subject to completion of financial statement closing procedures, indicating potential variability in actual results[7] - The company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2024[6] - The company emphasizes the importance of not placing undue reliance on preliminary estimates of financial condition[7] Business Development - Beam Therapeutics announced progress across its base editing portfolio and outlined key anticipated milestones in a press release dated January 13, 2025[11] - The company is focused on developing life-long, curative, precision genetic medicines for patients through base editing technology[12] - The company plans to advance its clinical trial designs and expectations for product candidates BEAM-101, BEAM-103, BEAM-301, and BEAM-302[12] Future Outlook - The company is preparing for presentations at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025[9] - Forward-looking statements include expectations related to the therapeutic applications of the company's technology for conditions such as SCD, AATD, GSD1a, and beta thalassemia[12] - The company faces risks related to the development and commercialization of its product candidates, including regulatory approval and funding availability[12]

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate ...

Core Insights - Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through base editing technology [2] Company Overview - Beam Therapeutics aims to establish a leading, fully integrated platform for precision genetic medicines, incorporating a suite of gene editing and delivery technologies [2] - The company is building internal manufacturing capabilities to support its gene editing technologies, particularly its proprietary base editing technology, which allows for precise and efficient single base changes in targeted genomic sequences without causing double-stranded breaks in DNA [2] - Beam is committed to providing life-long cures for patients with serious diseases and emphasizes its values-driven approach, focusing on its people and cutting-edge science [2] Upcoming Events - Management will participate in several investor conferences, including: - TD Cowen 45 Annual Health Care Conference on March 3, 2025, at 1:50 p.m. ET [3] - Leerink Partners Global Biopharma Conference on March 10, 2025, at 1:40 p.m. ET [3] - Barclays Global Healthcare Conference on March 11, 2025, at 3:30 p.m. ET [3] - Live webcasts of these events will be available on the company's website and archived for 60 days [1]

Group 1 - Beam Therapeutics Inc. (BEAM) shares have increased by 22.2% in the past four weeks, closing at $28.57, with a mean price target of $47.79 indicating a potential upside of 67.3% [1] - The average of 14 short-term price targets ranges from a low of $23 to a high of $80, with a standard deviation of $20.04, suggesting variability in analyst estimates [2] - Analysts show strong agreement on BEAM's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][9] Group 2 - The Zacks Consensus Estimate for BEAM's current year earnings has increased by 4.3% over the past month, with two estimates rising and no negative revisions [10] - BEAM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [11] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for price movement [12]

Group 1 - Beam Therapeutics Inc. (BEAM) has shown strong year-to-date performance, returning 10.5%, outperforming the Medical sector average of 5.6% [4] - The Zacks Consensus Estimate for BEAM's full-year earnings has increased by 7.5% over the past quarter, indicating improved analyst sentiment [4] - Beam Therapeutics is ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [3] Group 2 - Beam Therapeutics is part of the Medical - Biomedical and Genetics industry, which consists of 510 companies and is currently ranked 68 in the Zacks Industry Rank [6] - The average return for the Medical - Biomedical and Genetics industry so far this year is 4.3%, indicating that BEAM is performing better than its industry peers [6] - In contrast, Aurora Cannabis Inc. (ACB), another outperforming Medical stock, has returned 41.9% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5][7]

Company Overview - Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through base editing [3] - The company aims to establish a leading, fully integrated platform for precision genetic medicines, incorporating a suite of gene editing and delivery technologies [3] - Beam is building internal manufacturing capabilities to support its gene editing technologies, particularly its proprietary base editing technology [3] Upcoming Events - John Evans, the CEO of Beam Therapeutics, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 2:30 p.m. ET in New York [1] - A live webcast of the event will be available on the company's investor section of the website and will be archived for 60 days [2]